# PORTFOLIO_COURT_2026-09-03_DEEPAUDIT

## Inputs Consulted
- [[03_AGENT_RUNS/06_PORTFOLIO_COURT/_AGENT SPEC — Portfolio Court]] (role spec, read in full)
- [[03_AGENT_RUNS/05_UNDERWRITER/UNDERWRITER_2026-09-03_DEEPAUDIT]] (today's Deep Audit Underwriter output — fresh Monster Files for all 8 current holdings)
- [[01_MASTER_LEDGER/CAOS Master Ledger — CANONICAL]] (§1 mandate, §2 current portfolio snapshot, §4 role status, §11 draft sizing/count rules)
- [[02_ACTIVE_HANDOFF/CAOS — ACTIVE HANDOFF SNAPSHOT]] (open items: `20260902-DAILY-PORTFOLIO-COUNT_OVERAGE` Tribunal, `20260902-DAILY-WULF_IREN-EVIDENCE_GATE`, Challengers AMKR/MP, Watch SNDK, ONDS)

**Scope note:** This is a Deep Audit. Per task brief, every one of the 8 current holdings is run through the 100%-cash rebuild test explicitly, using the Underwriter's fresh inclusion/sizing/replacement findings as the evidentiary basis. This agent adjudicates the two open Active Handoff items routed to Deep Audit (portfolio-count/concentration overage; WULF/IREN sizing) but does not execute any trim, does not underwrite new candidates itself, and does not write to the Master Ledger. No exact share counts or trade instructions appear anywhere below — rankings and recommendations only.

**Note on Master Ledger §11 status:** the count cap, sizing norms, and Seed floor cited throughout are explicitly labeled DRAFT in the Ledger, pending Mark's confirmation. This agent applies them as the best available working standard because the Active Handoff routed both open items here for adjudication against them, and because Cash Is Valid / Concentration Is Allowed, Not Worshiped require *some* explicit norm to test against — but every finding below that rests on §11 is flagged CAOS INFERENCE applying a draft rule, not a confirmed breach of a ratified policy, and final ratification of §11 itself remains Mark's decision.

---

## 1. 100%-Cash Trial — Per Holding

Test: "If all capital were cash today, would CAOS buy this holding back, at its current size/weight/role?" Answer has two parts per holding: (a) inclusion — would CAOS buy *any* position — and (b) sizing — would CAOS buy it back *at its current weight*.

| Ticker | Weight | Inclusion (buy some?) | Buy back at CURRENT weight? | Verdict |
|---|---|---|---|---|
| PLTR | ~35.6% | YES — VERIFIED FACT revenue/growth trajectory (Underwriter) | **NO** | Would rebuild a position; not at 35.6%. Current weight is ~7x the ~5% draft Core/Attacker norm. Evidence supports the business; it does not support this concentration. |
| NVDA | ~29.8% | YES — VERIFIED FACT revenue/margin trajectory (Underwriter) | **NO** | Would rebuild a position; not at 29.8% (~6x draft norm). Same structural finding as PLTR: business case intact, size not evidence-justified. |
| MSFT | ~9.0% | YES | **MARGINAL YES** | ~1.8x the draft norm — a modest, not severe, overage. On a fresh 100%-cash build, this agent would likely land close to, not exactly at, the current weight. Not a priority sizing question. |
| KO | ~9.0% | **MARGINAL** — inclusion "strains against the mandate" per Underwriter (Objective = maximize CAGR; KO is the lowest-convexity name in the book) | **NO** | Would not rebuild a ~9.0% staples position from 100% cash under a CAGR-maximization mandate with 40% drawdown tolerance. Business quality is not in question; mandate fit is. This is the clearest "cash-first would not replicate current weight" case after PLTR/NVDA, and unlike PLTR/NVDA the issue is not excess-of-a-good-thing — it is a role mismatch. |
| GOOGL | ~5.8% | YES | **YES** | Closest of any holding to the ~5% draft norm; a fresh cash build would land here or very near it. No material sizing finding. |
| TSLA | ~5.5% | **YES on the verified EV-delivery-recovery thesis alone; NO additional weight can be justified on Optimus**, which Underwriter rates raw-convexity UNKNOWN pending verification, not credible | **YES, but on a narrower thesis than currently priced in** | Weight itself (~5.5%) is in line with the draft norm, so a cash rebuild would plausibly still land near here on the delivery-recovery case alone. The finding for Portfolio Court is about thesis quality, not size: if Optimus verification keeps failing to close, the *justification* for holding this weight erodes even though the arithmetic sizing does not currently flag an overage. |
| IREN | ~2.7% | **MARGINAL** — real AI Cloud contract growth (VERIFIED FACT on trajectory) but Underwriter finds a $11B–$16B unclosed FY27 financing gap, adjusted attractiveness LOW-TO-MODERATE | **YES, at this size, not larger** | Below the ~5% norm, above the Seed floor. A 100%-cash rebuild would plausibly still take a small position here given real revenue momentum, but the size should not grow until the financing gap gets a named source. Current small weight is not a violation; it is arguably the evidence-correct outcome already. |
| WULF | ~2.5% | **NO, not affirmatively — inclusion is "the most evidence-thin of any holding this run"** (Underwriter): the ~$19B Anthropic contract, the single number driving the thesis, rests on an unverified counterparty-credit claim this Deep Audit's Industry pass could not substantiate (tooling-blocked, not resolved) | **NO increase; current smallest-position size is the outcome a cash-first process would already produce, if it bought at all** | This is the sharpest finding of the 100%-cash trial. On a strict reading of Burden of Proof, a 100%-cash process today would **not** initiate a new WULF position on the current evidence — the defining number (~$19B contracted revenue) cannot be verified as investment-grade-backed, and Survivability Before Optionality flags the leverage (~63% naive debt+equity) stacked on top of an unrated single-counterparty bet. The fact that WULF is already the smallest position in the book is not a coincidence to be corrected upward; if anything it is the closest the current portfolio comes to already expressing this finding. **Portfolio Court does not recommend an immediate exit** (the evidence gate is open, not closed negative — Radical Honesty requires distinguishing "unresolved" from "disproven") but flags WULF as the one holding that fails its own 100%-cash trial most cleanly of the 8. |

**Summary of the cash trial:** 5 of 8 holdings (NVDA, PLTR on inclusion; MSFT, GOOGL, TSLA, IREN) pass inclusion cleanly. Two holdings (PLTR, NVDA) fail the *sizing* leg of the trial decisively. One holding (KO) has a marginal inclusion case against this specific mandate and fails sizing. One holding (WULF) has the weakest inclusion case of the eight on current evidence, though its current (smallest) size already understates rather than overstates that weakness.

---

## 2. Next-Uncommitted-Euro Ranking

This ranks where the next real euro of capital (the €300/month contribution, or capital freed by any future trim) should go, tested against cash and every current holding/candidate. Per **Cash Is Valid**, "do nothing" beats every option below whenever none clears the bar; per **Concentration Is Allowed, Not Worshiped**, size alone is never disqualifying — only lack of opportunity-cost justification is.

**Do NOT deploy the next euro toward (ranked by how clearly disqualified):**
1. **PLTR / NVDA** — already ~7x and ~6x the draft sizing norm respectively. Adding to either without first resolving the existing overage would deepen the single largest risk finding in this Deep Audit. Disqualified for new capital regardless of business quality.
2. **WULF** — LOW adjusted attractiveness this cycle specifically because the Anthropic-credit gate remains open (Underwriter). New capital here before that gate closes would be sizing into an unresolved Burden-of-Proof failure.
3. **KO** — mandate-fit question (lowest convexity name in a CAGR-maximization book), already above the draft norm. New capital better spent elsewhere.
4. **IREN** — real momentum, but the $11B–$16B FY27 financing gap is unclosed; adding weight ahead of a named financing source is premature.
5. **TSLA** — in-line weight, but new capital should wait on Optimus verification before adding beyond the already-justified delivery-recovery-sized position.

**Rank order for where the next euro SHOULD go, highest priority first:**
1. **GOOGL** — highest-ranked destination. Near-norm weight (~5.8%), MODERATE-HIGH adjusted attractiveness, HIGH-quality VERIFIED FACT evidence (Cloud +82% YoY, $514B backlog), lowest replacement risk of the growth names, and — critically — topping up here does not deepen any existing overage.
2. **MSFT** — second priority. Modest existing overweight (~1.8x norm) but MODERATE-HIGH adjusted attractiveness and durable, diversified AI-demand exposure; a smaller top-up than GOOGL is still defensible given the milder starting overage.
3. **AMKR (Challenger, not yet funded)** — HIGH evidence quality (SEC 8-K sourced), profitable incumbent, no dilution signal, direct CoWoS/advanced-packaging bottleneck beneficiary. Ranked ahead of adding to any current holding **on pure evidence merit**, but funding a 9th security is gated by the count-overage question in §4 below — this is a "ready capital, no open slot" case, not a quality problem.
4. **MP (Challenger, not yet funded)** — MEDIUM evidence quality; the unresolved $400M-vs-$550M+ DoD-support figure discrepancy is a real, closeable gap that should be reconciled before this ranks above AMKR.
5. **Cash** — given Verifier's DATA QUALITY = DEGRADED finding on equity-quote reliability (TSLA/IREN/WULF prices internally conflicting across sources) carried into this Deep Audit, a portion of the next contribution held as cash pending a clean price reconciliation is a legitimate, non-default choice, not merely an absence of action.

ONDS and SNDK remain WATCH-tier per the Active Handoff; neither has cleared Underwriter depth this cycle and neither is ranked above.

---

## 3. Capital-Recycling Tribunal

**Question posed:** should the excess weight trapped in the two most overweight names be recycled, and if so, toward what?

**Finding:** YES, in principle. The combined ~65.4% of holdings currently sitting in PLTR + NVDA is not, per the Underwriter's own two-field discipline, an evidence problem — raw convexity and adjusted attractiveness for both names remain MODERATE-to-MODERATE-HIGH. It is a **concentration-versus-opportunity-cost** problem: capital held at 6–7x the draft Core/Attacker norm in two names is capital not available to GOOGL/MSFT (both evidence-ranked comparably high, per §2), to a count-cap-compliant AMKR entry, or to closing IREN's financing-gap-driven underweight once that gap closes. Per **Concentration Is Allowed, Not Worshiped**, the test is whether this concentration is *earning* its opportunity cost — and at 7x/6x the norm, against otherwise-comparable-quality alternatives sitting underweight or unfunded, this agent's ranking finds it is not earning the *full* magnitude of the current overweight, even though some premium above 5% is defensible for both names given evidence quality.

**Recycling destination ranking (if/when any PLTR/NVDA trim capital is realized — this agent does not size or order the trim itself):**
1. Close the GOOGL/MSFT underweight/marginal-overweight first (§2 ranks 1–2) — same-tier evidence quality, lower concentration risk, zero count-cap cost.
2. Fund an AMKR entry **contingent on** the count-overage resolution in §4 opening a slot — do not add a 9th funded security ahead of that resolution.
3. Hold a portion as cash given the DEGRADED price-data finding, rather than force-deploying 100% of any freed capital immediately.

**This agent does not recommend recycling KO's or WULF's capital into PLTR/NVDA or vice versa** — that would concentrate further into names already flagged, not reduce concentration risk.

---

## 4. Portfolio-Count and No-Orphan Check

### Portfolio-count check: **OVERAGE CONFIRMED, adjudicated**
The portfolio holds 8 funded securities against Master Ledger §11's draft 7-security cap. Per the Active Handoff routing (`20260902-DAILY-PORTFOLIO-COUNT_OVERAGE`), this Deep Audit adjudicates the count and the PLTR/NVDA sizing overage together, as instructed, rather than treating them as separate questions — they are the same underlying finding (too much capital committed to too few/too concentrated names) viewed from two angles.

**Adjudication:**
- The count breach (8 vs. 7) and the sizing breach (PLTR ~35.6%, NVDA ~29.8% vs. ~5% norm) are **not independent problems requiring independent fixes**. If the sizing overage in PLTR/NVDA is addressed by any future trim, the count question does not resolve itself automatically — count and dollar-concentration are separate axes (a portfolio can hold 8 modestly-sized names, or 6 lopsided ones) — so both remain live even after each other's resolution and must be tracked separately.
- **On the count axis specifically**: if the draft 7-cap is confirmed by Mark, this agent's ranking of which current holding is the most defensible candidate to exit first (to bring the count to 7) is, in priority order:
  1. **WULF** — smallest position (~2.5%), LOW adjusted attractiveness this cycle specifically (unresolved Anthropic-credit gate, Burden of Proof not met, per §1 above), lowest replacement risk to unwind (does not require selling into strength on a working thesis, and Discovery-tier alternatives — AMKR — already offer cleaner-financed AI-supply-chain exposure per Underwriter).
  2. **KO** — mandate-fit case (§1), larger position (~9.0%) than WULF so a harder capital-efficiency case to make, but the softer of the two justifications (KO's business is not impaired; it is simply a lower-convexity fit for this specific mandate).
  3. **IREN** — only reaches this ranking if WULF's gate resolves negatively as well and IREN's own financing gap fails to close by its Q1 FY2027 checkpoint; currently ranked below both because Underwriter's inclusion case for IREN is stronger (AI Cloud contract growth, VERIFIED FACT trajectory) than WULF's.
- **This agent does not execute an exit.** This is a ranking of exit priority, not an instruction. §11's cap remains DRAFT pending Mark's explicit confirmation — until then, this ranking is the standing recommendation, not a binding block.

### Concentration overage (PLTR ~35.6%, NVDA ~29.8%): **CONFIRMED, adjudicated**
Reconfirmed independently in §1 and §3 above. Per **Concentration Is Allowed, Not Worshiped**, this agent's finding is that both positions justify *some* premium above the 5% draft norm on evidence quality alone, but not the current multiple (6–7x). This agent does not set a replacement ceiling number (that would stray toward sizing/execution); it ranks the excess weight as the top capital-recycling priority in §3 and defers the exact target weight to Mark's confirmation of §11 and to Execution once a direction is set.

### WULF/IREN sizing question: **adjudicated**
Per the task brief's specific instruction to weigh in given Underwriter's LOW rating on WULF: **this agent does not recommend increasing WULF's size**, and ranks it the top exit-priority candidate if the count cap is confirmed (above). IREN's smaller current weight is judged evidence-appropriate already — not itself a violation requiring correction, only a hold-not-grow position pending its financing-gap checkpoint. The two names should not be treated as a single fungible "AI-pivot bucket" for sizing purposes: WULF's evidence gate (counterparty credit, unresolved) and IREN's evidence gap (financing sources, unresolved) are different failure modes, and Red Team's own finding (carried in the Active Handoff) that the "WULF riskier than IREN" framing was directionally correct but magnitude-overstated across the report chain is reaffirmed here independently — the two are close, not identical, and neither should be added to on current evidence.

### No-Orphan check: **PASS**
Per §11 draft rule: "permanent sub-1% orphans are prohibited." The smallest current holding is WULF at ~2.5% of holdings, followed by IREN at ~2.7% — both above the ~1.5% sub-floor that would trigger an explicit Seed/Catalyst-role requirement, and both well above the 1% orphan threshold. **No orphan violation exists in the current 8-holding book.**

**Separately flagged (role-label mismatch, not a No-Orphan violation):** Underwriter flags that IREN's and WULF's inherited "CORE/ATTACKER" role label (Ledger §4: all 8 holdings are inherited, pre-CAOS, role assignment still pending) may not fit their actual risk profile as well as an explicit Seed/Catalyst-with-evidence-gate role would. This agent concurs this is worth Mark's attention at the next role-assignment review but treats it as a **role-label question, not a No-Orphan or sizing violation** — both positions clear the 1.5% Seed floor comfortably, so no rule is currently broken by the label as inherited.

---

## What This Run Explicitly Does Not Do
- Does not output exact share counts, trade sizes, or a buy/sell instruction anywhere above — every recommendation is a ranking or a recommendation for Mark's/Execution's downstream action.
- Does not set a numeric target ceiling for PLTR/NVDA's post-trim weight — that is a sizing decision for Mark/Execution once §11 is confirmed, not a ranking question.
- Does not close the WULF/IREN Anthropic-credit evidence gate — that remains Industry/Verifier's job on next-cycle egress access, per Underwriter's explicit recommendation.
- Does not underwrite AMKR, MP, ONDS, or SNDK to Monster File depth — ranks them using only the evidence quality already on record in the Active Handoff Snapshot.
- Does not write to the Master Ledger or Active Handoff Snapshot directly.

---

## Verdict

`PORTFOLIO COURT = RANKING COMPLETE`
